Cellectar Biosciences Inc
CLRB2.760USD
+0.070+2.60%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
8.81MMarket Cap
LossP/E TTM
More Details of Cellectar Biosciences Inc Company
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Cellectar Biosciences Inc Info
Ticker SymbolCLRB
Company nameCellectar Biosciences Inc
IPO dateMay 20, 2005
CEOCaruso (James V)
Number of employees11
Security typeOrdinary Share
Fiscal year-endMay 20
Address100 Campus Drive
CityFLORHAM PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07932
Phone16084418120
Websitehttps://www.cellectar.com/
Ticker SymbolCLRB
IPO dateMay 20, 2005
CEOCaruso (James V)
Company Executives of Cellectar Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Mr. John P. Neis
Mr. John P. Neis
Independent Director
Independent Director
--
--
Dr. Asher Alban Chanan-Khan, M.D.
Dr. Asher Alban Chanan-Khan, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hexstone Capital LLC
3.54%
Bleichroeder LP
2.36%
The Vanguard Group, Inc.
1.54%
Renaissance Technologies LLC
0.59%
Geode Capital Management, L.L.C.
0.59%
Other
91.39%
Shareholders
Shareholders
Proportion
Hexstone Capital LLC
3.54%
Bleichroeder LP
2.36%
The Vanguard Group, Inc.
1.54%
Renaissance Technologies LLC
0.59%
Geode Capital Management, L.L.C.
0.59%
Other
91.39%
Shareholder Types
Shareholders
Proportion
Investment Advisor
5.02%
Corporation
3.77%
Hedge Fund
1.08%
Investment Advisor/Hedge Fund
0.89%
Individual Investor
0.73%
Bank and Trust
0.02%
Other
88.49%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
75
297.26K
10.12%
--
2025Q3
78
297.60K
13.55%
+188.16K
2025Q2
77
104.84K
25.74%
-85.88K
2025Q1
75
173.87K
34.08%
-349.52K
2024Q4
73
170.23K
32.62%
-296.95K
2024Q3
71
467.18K
32.75%
+48.19K
2024Q2
77
387.52K
26.59%
+82.11K
2024Q1
73
305.41K
30.77%
-34.71K
2023Q4
61
267.30K
23.82%
+113.45K
2023Q3
63
103.32K
23.03%
-3.51K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hexstone Capital LLC
150.00K
4.7%
+150.00K
--
Jul 02, 2025
The Vanguard Group, Inc.
56.34K
1.76%
-1.05K
-1.84%
Jun 30, 2025
Geode Capital Management, L.L.C.
14.44K
0.45%
-342.00
-2.31%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.60K
0.14%
--
--
Aug 31, 2025
Longcor (Jarrod)
12.77K
0.4%
+10.00K
+360.88%
Jul 02, 2025
Caruso (James V)
11.64K
0.36%
+10.00K
+609.38%
Jul 02, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 18, 2025
Merger
30→1
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
Date
Type
Ratio
Jun 18, 2025
Merger
30→1
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
Jul 21, 2022
Merger
10→1
FAQs
Who are the top five shareholders of Cellectar Biosciences Inc?
The top five shareholders of Cellectar Biosciences Inc are:
Hexstone Capital LLC holds 150.00K shares, accounting for 4.70% of the total shares.
The Vanguard Group, Inc. holds 56.34K shares, accounting for 1.76% of the total shares.
Geode Capital Management, L.L.C. holds 14.44K shares, accounting for 0.45% of the total shares.
Dimensional Fund Advisors, L.P. holds 4.60K shares, accounting for 0.14% of the total shares.
Longcor (Jarrod) holds 12.77K shares, accounting for 0.40% of the total shares.
Hexstone Capital LLC holds 150.00K shares, accounting for 4.70% of the total shares.
The Vanguard Group, Inc. holds 56.34K shares, accounting for 1.76% of the total shares.
Geode Capital Management, L.L.C. holds 14.44K shares, accounting for 0.45% of the total shares.
Dimensional Fund Advisors, L.P. holds 4.60K shares, accounting for 0.14% of the total shares.
Longcor (Jarrod) holds 12.77K shares, accounting for 0.40% of the total shares.
What are the top three shareholder types of Cellectar Biosciences Inc?
The top three shareholder types of Cellectar Biosciences Inc are:
Hexstone Capital LLC
Bleichroeder LP
The Vanguard Group, Inc.
Hexstone Capital LLC
Bleichroeder LP
The Vanguard Group, Inc.
How many institutions hold shares of Cellectar Biosciences Inc (CLRB)?
As of 2025Q4, 75 institutions hold shares of Cellectar Biosciences Inc, with a combined market value of approximately 297.26K, accounting for 10.12% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.43%.
What is the biggest source of revenue for Cellectar Biosciences Inc?
In --, the -- business generated the highest revenue for Cellectar Biosciences Inc, amounting to -- and accounting for --% of total revenue.
